1.WHO Global Health Observatory

Number of new HIV infections: estimates by WHO region.

2.

UNAIDS data 2018.

3.Okwundu CI Uthman OA Okoromah CA

Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals.

Cochrane Database Syst Rev. 7CD0071894.Grulich AE Guy R Amin J et al.

Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study.

Lancet HIV. 5: e629-e6375.Siegler AJ Mouhanna F Giler RM et al.

The prevalence of pre-exposure prophylaxis use and the pre-exposure prophylaxis-to-need ratio in the fourth quarter of 2017, United States.

Ann Epidemiol. 28: 841-8496.Mayer KH Agwu A Malebranche D

Barriers to the wider use of pre-exposure prophylaxis in the United States: a narrative review.

Adv Ther. 37: 1778-18117.Tetteh RA Yankey BA Nartey ET Lartey M Leufkens HG Dodoo AN

Pre-exposure prophylaxis for HIV prevention: safety concerns.

Drug Saf. 40: 273-2838.

Tenofovir and bone health.

Curr Opin HIV AIDS. 11: 326-3329.Arribas JR Thompson M Sax PE et al.

Brief report: randomized, double-blind comparison of tenofovir alafenamide (TAF) vs tenofovir disoproxil fumarate (TDF), each coformulated with elvitegravir, cobicistat, and emtricitabine (E/C/F) for initial HIV-1 treatment: week 144 results.

J Acquir Immune Defic Syndr. 75: 211-21810.Gupta SK Post FA Arribas JR et al.

Renal safety of tenofovir alafenamide vs tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials.

AIDS. 33: 1455-146511.Mayer KH Molina JM Thompson MA et al.

Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.

Lancet. 396: 239-25412.US Centers for Disease Control and Prevention

2015 sexually transmitted diseases treatment guidelines.

13.

The efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in antiretroviral regimens for HIV-1 therapy: meta-analysis.

Medicine (Baltimore). 95e514614.National Kidney Foundation

K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.

Am J Kidney Dis. 39: S1-26615.

A simple method to calculate the confidence interval of a standardized mortality ratio (SMR).

Am J Epidemiol. 131: 373-37516.

Randomization-based nonparametric analysis of covariance (ANCOVA).

in: D'Agostino Sr, RB Sullivan LM Massaro JM Wiley Encyclopedia of Clinical Trials. vol 4. John Wiley & Sons, Hoboken: 31-3817.Walsh JS Henry YM Fatayerji D Eastell R

Lumbar spine peak bone mass and bone turnover in men and women: a longitudinal study.

Osteoporos Int. 20: 355-36218.Weaver CM Gordon CM Janz KF et al.

The National Osteoporosis Foundation's position statement on peak bone mass development and lifestyle factors: a systematic review and implementation recommendations.

Osteoporos Int. 27: 1281-138619.Dimitrov DT Mâsse BR Donnell D

PrEP adherence patterns strongly impact individual HIV risk and observed efficacy in randomized clinical trials.

J Acquir Immune Defic Syndr. 72: 444-45120.US Centers for Disease Control and Prevention (CDC)

Effectiveness of prevention strategies to reduce the risk of acquiring or transmitting HIV.

21.

Landovitz RJ, Donnell D, Clement M, et al. HPTN 083 interim results: pre-exposure prophylaxis (PrEP) containing long-acting injectable cabotegravir (CAB-LA) is safe and highly effective for cisgender men and transgender women who have sex with men (MSM, TGW). AIDS 2020 (virtual); July 6–10, 2020 (abstr 10750).

22.Massud I Cong ME Ruone S et al.

Efficacy of oral tenofovir alafenamide/emtricitabine combination or single-agent tenofovir alafenamide against vaginal simian human immunodeficiency virus infection in macaques.

J Infect Dis. 220: 1826-183323.

Lack of effect of tenofovir disoproxil fumarate on pharmacokinetics of hormonal contraceptives.

Pharmacotherapy. 29: 924-92924.

Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) US prescribing information.

25.Center for Drug Evaluation and Research

Multi-discipline review: biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide).

26.American Academy of Orthopaedic Surgeons

Healthy bones at every age.

27.Ruane PJ DeJesus E Berger D et al.

Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults.

J Acquir Immune Defic Syndr. 63: 449-45528.Samuels R Bayerri CR Sayer JA Price DA Payne BAI

Tenofovir disoproxil fumarate-associated renal tubular dysfunction: noninvasive assessment of mitochondrial injury.

AIDS. 31: 1297-130129.Glidden DV Mulligan K McMahan V et al.

Metabolic effects of preexposure prophylaxis with coformulated tenofovir disoproxil fumarate and emtricitabine.

Clin Infect Dis. 67: 411-41930.Landovitz RJ Li S Grinsztejn B et al.

Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial.

PLoS Med. 15e100269031.Zamora D Gordon-Larsen P Jacobs Jr, DR Popkin BM

Diet quality and weight gain among black and white young adults: the Coronary Artery Risk Development in Young Adults (CARDIA) Study (1985–2005).

Am J Clin Nutr. 92: 784-79332.Randell PA Jackson AG Zhong L Yale K Moyle GJ

The effect of tenofovir disoproxil fumarate on whole-body insulin sensitivity, lipids and adipokines in healthy volunteers.

Antivir Ther. 15: 227-233